- Home
- RLAY vs KOD Comparison
RLAY vs KOD Comparison
Compare RLAY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- KOD
- Stock Information
- Founded
- RLAY 2015
- KOD 2009
- Country
- RLAY United States
- KOD United States
- Employees
- RLAY N/A
- KOD N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLAY Health Care
- KOD Health Care
- Exchange
- RLAY Nasdaq
- KOD Nasdaq
- Market Cap
- RLAY 803.4M
- KOD 795.5M
- IPO Year
- RLAY 2020
- KOD 2018
- Fundamental
- Price
- RLAY $6.22
- KOD $11.72
- Analyst Decision
- RLAY Strong Buy
- KOD Buy
- Analyst Count
- RLAY 8
- KOD 6
- Target Price
- RLAY $17.25
- KOD $14.33
- AVG Volume (30 Days)
- RLAY 1.7M
- KOD 1.1M
- Earning Date
- RLAY 11-05-2025
- KOD 11-13-2025
- Dividend Yield
- RLAY N/A
- KOD N/A
- EPS Growth
- RLAY N/A
- KOD N/A
- EPS
- RLAY N/A
- KOD N/A
- Revenue
- RLAY $8,355,000.00
- KOD N/A
- Revenue This Year
- RLAY $27.33
- KOD N/A
- Revenue Next Year
- RLAY $7.40
- KOD N/A
- P/E Ratio
- RLAY N/A
- KOD N/A
- Revenue Growth
- RLAY N/A
- KOD N/A
- 52 Week Low
- RLAY $1.78
- KOD $1.92
- 52 Week High
- RLAY $7.07
- KOD $19.39
- Technical
- Relative Strength Index (RSI)
- RLAY 71.34
- KOD 45.51
- Support Level
- RLAY $5.47
- KOD $11.42
- Resistance Level
- RLAY $7.00
- KOD $15.01
- Average True Range (ATR)
- RLAY 0.37
- KOD 1.75
- MACD
- RLAY 0.11
- KOD -0.49
- Stochastic Oscillator
- RLAY 70.90
- KOD 3.76
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.